Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $326,520.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,721 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the sale, the senior vice president owned 3,114 shares in the company, valued at $373,680. The trade was a 46.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Stock Performance

MIRM traded up $5.13 during trading on Thursday, reaching $125.59. 653,000 shares of the company were exchanged, compared to its average volume of 936,409. The stock has a market cap of $7.66 billion, a P/E ratio of -9.23 and a beta of 0.48. The firm has a 50 day moving average of $101.93 and a 200 day moving average of $95.13. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 52 week low of $49.01 and a 52 week high of $125.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same period in the prior year, the business earned ($0.30) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at $32,000. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at $33,000. Finally, Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period.

Analyst Ratings Changes

A number of research analysts have issued reports on MIRM shares. HC Wainwright reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a report on Thursday, May 7th. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Finally, Citizens Jmp raised their target price on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $143.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.